Abiraterone acetate（154229-18-2）

Overview: Abiteron acetate was initially developed by the British Cancer Research Institute and BTG, and then transferred the global development right and listing right to Cougar Bio-pharmaceutical Company (now a subsidiary of Johnson&Johnson). On April 28, 2011, Abitherone acetate was approved for the first time in the United States, with the trade name of Zytiga, an oral tablet of 250mg, in combination with prednisone for the treatment of castration resistant prostate cancer (cRPC), which cannot be controlled by docetaxel.

Application: Abitherone acetate is a CYP17 inhibitor, which can be used in combination with prednisone to treat prostate cancer patients who have received docetaxel chemotherapy and metastasis. Abitherone acetate is a precursor drug, which can be converted into abitherone after entering the body. The latter is an androgen biosynthesis inhibitor, which exerts therapeutic effect by inhibiting the activity of CYP17 enzyme and then inhibiting androgen biosynthesis

PREVIOUS：Abiraterone（154229-19-3） NEXT：Dacinostat（404951-53-7）